Management of patients with diabetes and CKD: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference

Vlado Perkovic, Rajiv Agarwal, Paola Fioretto, Brenda R Hemmelgarn, Adeera Levin, Merlin C Thomas, Christoph Wanner, Bertram L Kasiske, David C Wheeler, Per-Henrik Groop, Conference Participants

106 Citationer (Scopus)

Abstract

The prevalence of diabetes around the world has reached epidemic proportions and is projected to increase to 642 million people by 2040. Diabetes is already the leading cause of end-stage kidney disease (ESKD) in most developed countries, and the growth in the number of people with ESKD around the world parallels the increase in diabetes. The presence of kidney disease is associated with a markedly elevated risk of cardiovascular disease and death in people with diabetes. Several new therapies and novel investigational agents targeting chronic kidney disease patients with diabetes are now under development. This conference was convened to assess our current state of knowledge regarding optimal glycemic control, current antidiabetic agents and their safety, and new therapies being developed to improve kidney function and cardiovascular outcomes for this vulnerable population.

OriginalsprogEngelsk
TidsskriftKidney International
Vol/bind90
Udgave nummer6
Sider (fra-til)1175-1183
Antal sider9
ISSN0085-2538
DOI
StatusUdgivet - dec. 2016
Udgivet eksterntJa

Fingeraftryk

Dyk ned i forskningsemnerne om 'Management of patients with diabetes and CKD: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference'. Sammen danner de et unikt fingeraftryk.

Citationsformater